Global Angioplasty Balloons Market Fueled by Rise in Obesity and Heart Diseases

The global market for angioplasty balloons, according to business intelligence firm Transparency Market Research, is projected to expand at a moderate CAGR of 3.50% from 2015 to 2023, rising from a value of US$1.7 bn in 2014 to US$2.5 bn by 2023. The report states that the growth of the angioplasty balloons market can be attributed to the rise in aging population, the spike in obesity rate, the growing prevalence of coronary artery disease, the continuous development and launch of new products, and the surge in unmet medical needs in emerging economies.

Escalating Prevalence of Coronary Artery Disease Driving Global Market

Angioplasty is a non-surgical procedure to treat blocked blood vessels and arteries. The alarming rise in the prevalence of coronary artery disease is one of the most prominent factors fueling the demand for angioplasty balloons today. According to the National Heart, Lung, and Blood Institute at the National Institutes of Health, coronary heart disease is a leading cause of death for both women and men in the US. An estimated 370,000 Americans die from coronary heart disease each year. The World Health Organization (WHO) states that in 2012, around 17.5 million people died from various cardiovascular diseases worldwide, of which, around 7.4 million died from coronary heart disease. Angioplasty is performed on over 600,000 patients in America each year, costing the US healthcare system around US$12 bn a year, according to a study published in the Journal of the American Medical Association.

The growing demand for angioplasty procedures has presented players within the market with several opportunities to expand their businesses. Capitalizing on the rising popularity of angioplasty balloons are companies such as Medtronic, ENDOCOR, C. R. Bard, Cook Medical, NATEC Medical, Spectranetics, Johnson & Johnson, Abbott Vascular, Boston Scientific, and BIOTRONIK.

Drug-eluting Balloon Angioplasty Better than Traditional Balloon Angioplasty

According to the recent findings of the PACUBA trial, angioplasty performed with a drug-eluting balloon to treat in-stent restenosis of the superficial femoral artery (SFA) presents a considerably improved patency at 12 months, in comparison with the plain-old balloon angioplasty. The findings, presented at the International Symposium on Endovascular Therapy in the second week of February, indicate that traditional balloon angioplasty is not the correct treatment for patients suffering from in-stent restenosis. An estimated 49.0% of patients treated with the drug-coated angioplasty balloon were free from target lesion revascularization at 12 months, compared to the 22.0% of patients undergoing angioplasty with the older balloons.

However, while drug-eluting angioplasty balloons beat the plain-old balloons, researchers state that the results are not entirely convincing and not very fascinating either. Johannes Lammer of the Medical University Vienna and lead investigator in the trial has said that there is still dire need for better therapies to treat the growing problem of in-stent restenosis of the SFA.

0 comments:

Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports